Search results for ERBB2

Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody#2249, Cell Signaling Technology (CST), 2249

Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody detects endogenous levels of ErbB2 only when phosphorylated at tyrosine 1221/1222. This antibody may detect other activated Erb family members.

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody#2165, Cell Signaling Technology (CST), 2165

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody detects endogenous levels of total ErbB2 protein. This antibody does not cross-react with related kinases.

HER2/ErbB2 (44E7) Mouse Monoclonal Antibody#2248, Cell Signaling Technology (CST), 2248

HER2/ErbB2 (44E7) Mouse Monoclonal Antibody detects transfected or over-expressed levels of HER2/ErbB2 protein. This antibody does not cross-react with any other related proteins.

HER2/ErbB2 (D8F12) Rabbit Monoclonal Antibody#4290, Cell Signaling Technology (CST), 4290

HER2/ErbB2 (D8F12) Rabbit Monoclonal Antibody detects endogenous levels of total HER/ErbB2 protein. This antibody may cross-react slightly with other overexpressed RTKs.

Runimotamab Biosimilar – Anti-ERBB2;CD3E mAb – Research Grade, ProteoGenix, PX-TA1713

Description of Runimotamab Biosimilar - Anti-ERBB2;CD3E mAb - Research Grade Introduction Runimotamab Biosimilar, also known as Anti-ERBB2,CD3E mAb, is a monoclonal antibody that has been developed as a biosimilar to the original drug, trastuzumab. It is a targeted therapy that specifically binds to the HER2 receptor (ERBB2) and the CD3E protein on the surface of cancer cells. This article will provide a scientific description of the structure, activity, and application of Runimotamab Biosimilar in research grade. Structure of Runimotamab Biosimilar Runimotamab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced in a laboratory using human DNA sequences. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains are approximately 50 kDa in size, while the light chains are about 25 kDa. The antibody has a molecular weight of approximately 150 kDa. The variable regions of the antibody, responsible for binding to the target proteins, are derived from the original trastuzumab antibody. However, the constant regions have been modified to make it more similar to the human immune system, reducing the risk of immune reactions. Activity of Runimotamab Biosimilar Runimotamab Biosimilar works by binding to the HER2 receptor and the CD3E protein on the surface of cancer cells. The HER2 receptor is overexpressed in some types of cancer, including breast, gastric, and ovarian cancer. This overexpression leads to uncontrolled cell growth and proliferation. By binding to the HER2 receptor, Runimotamab Biosimilar blocks the signaling pathways that promote cancer growth, inhibiting tumor growth. In addition, Runimotamab Biosimilar also binds to the CD3E protein, which is found on the surface of T cells. This binding activates the T cells, triggering an immune response against the cancer cells. This dual mechanism of action makes Runimotamab Biosimilar a potent targeted therapy for HER2-positive cancers. Application of Runimotamab Biosimilar Runimotamab Biosimilar is currently being used in research grade for the treatment of HER2-positive cancers, particularly breast cancer. It is being studied in clinical trials as a potential alternative to trastuzumab, with the aim of providing a more affordable treatment option. In addition, Runimotamab Biosimilar is also being investigated for the treatment of other HER2-positive cancers, such as gastric and ovarian cancer. It has shown promising results in preclinical studies and is expected to enter clinical trials for these indications in the near future. Conclusion In summary, Runimotamab Biosimilar is a recombinant humanized monoclonal antibody that targets the HER2 receptor and the CD3E protein on cancer cells. Its structure, derived from the original trastuzumab antibody, and its dual mechanism of action make it a potent targeted therapy for HER2-positive cancers. As a biosimilar, it has the potential to provide a more affordable treatment option for patients. Ongoing research and clinical trials are expected to further establish the efficacy and safety of Runimotamab Biosimilar in the treatment of HER2-positive cancers.

Zenocutuzumab Biosimilar – Anti-ERBB2, ERBB3 mAb – Research Grade, ProteoGenix, PX-TA1493

Description of Zenocutuzumab Biosimilar - Anti-ERBB2, ERBB3 mAb - Research Grade Introduction Zenocutuzumab Biosimilar, also known as Anti-ERBB2, ERBB3 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for the treatment of various cancers. This biosimilar is a highly specific and potent inhibitor of the ERBB2 and ERBB3 receptors, which are known to play a crucial role in the growth and survival of cancer cells. In this article, we will discuss the structure, activity, and potential applications of Zenocutuzumab Biosimilar in the field of cancer research. Structure of Zenocutuzumab Biosimilar Zenocutuzumab Biosimilar is a recombinant humanized monoclonal antibody that has been designed to target and block the activity of the ERBB2 and ERBB3 receptors. It is a biosimilar of the original Zenocutuzumab, which is a fully humanized monoclonal antibody. The biosimilar version has been developed using advanced biotechnological techniques, which ensure high levels of purity and consistency in its structure. The antibody is composed of two heavy chains and two light chains, which are linked by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL1) and one variable domain (VL). The variable domains are responsible for binding to the specific target receptors, while the constant domains provide stability and effector functions. Mechanism of Action Zenocutuzumab Biosimilar exerts its anti- cancer activity by specifically binding to the extracellular domains of the ERBB2 and ERBB3 receptors, which are overexpressed in various types of cancer cells. This binding prevents the activation of downstream signaling pathways, which are responsible for promoting cell growth and survival. Additionally, the antibody also triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cancer cells. Therapeutic Target: ERBB2 and ERBB3 Receptors The ERBB2 and ERBB3 receptors, also known as HER2 and HER3, respectively, belong to the epidermal growth factor receptor (EGFR) family. These receptors are often overexpressed in various types of cancer cells, including breast, lung, and gastric cancers. Overexpression of these receptors is associated with aggressive tumor growth, resistance to chemotherapy, and poor prognosis. Zenocutuzumab Biosimilar specifically targets these receptors, inhibiting their activity and preventing the growth and survival of cancer cells. This makes it a promising therapeutic agent for the treatment of HER2-positive and HER3-positive cancers. Potential Applications Zenocutuzumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. It has the potential to be used as a monotherapy or in combination with other anti- cancer agents. Some of the potential applications of Zenocutuzumab Biosimilar include: – Treatment of HER2-positive breast cancer: Zenocutuzumab Biosimilar has shown promising results in HER2-positive breast cancer, both as a single agent and in combination with other anti- cancer drugs. – Treatment of HER3-positive lung cancer: Zenocutuzumab Biosimilar has shown efficacy in preclinical studies against HER3-positive lung cancer, which is often resistant to traditional chemotherapy. – Treatment of HER2-positive gastric cancer: Zenocutuzumab Biosimilar has shown promising results in preclinical studies against HER2-positive gastric cancer, which is a highly aggressive and difficult-to-treat cancer. Conclusion In conclusion, Zenocutuzumab Biosimilar is a highly specific and potent monoclonal antibody that targets the ERBB2 and ERBB3 receptors, which are overexpressed in various types of cancer cells. Its unique mechanism

HER2/ErbB2 (D8F12) Rabbit Monoclonal Antibody (Biotinylated)#8609, Cell Signaling Technology (CST), 8609

HER2/ErbB2 (D8F12) Rabbit Monoclonal Antibody (Biotinylated) detects endogenous levels of total HER2/ErbB2 protein.

Phospho-HER2/ErbB2 (Tyr1248)/EGFR (Tyr1173) Antibody#2244, Cell Signaling Technology (CST), 2244

Phospho-HER2/ErbB2 (Tyr1248)/EGFR (Tyr1173) Antibody detects ErbB2 only when phosphorylated at tyrosine 1248 and EGFR only when phosphorylated at tyrosine 1173.

Anti-Human CD340/ERBB2/HER2 Nanobody (11A4) (HY286053), abinScience, HY286053

Anti-Human CD340/ERBB2/HER2 Nanobody (SAA0836) (HY286013), abinScience, HY286013